Amgen has posted results from its 52-week Open Label Study of Long TERm Evaluation Against LDL-C (OSLER) Phase II trial, a safety and efficacy study. The study showed that monthly treatment with evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood was not associated with a major increase in adverse events...